Selected research from leading health care experts whose findings have a direct bearing on public policies effecting medical progress. Research is chosen based on its quality and relevance by the Medical Progress Today editorial staff.

Selected Research

The Value of Antihypertensive Drugs: A perspective on medical innovation
David M. Cutler, Health Affairs, 1-17-07

Cutler and his colleagues estimate the economic and health impacts of antihypertensive therapy in the U.S. over the past 40 years.

Using national survey data and risk equations from the Framingham Heart Study, we quantify the impact of antihypertensive therapy changes on blood pressures and the number and cost of heart attacks, strokes, and deaths. Antihypertensive therapy has had a major impact on health. Without it, 1999–2000 average blood pressures (at age 40+) would have been 10–13 percent higher, and 86,000 excess premature deaths from cardiovascular disease would have occurred in 2001. Treatment has generated a benefit–to–cost ratio of at least 6:1, but much more can be achieved. More effective use of antihypertensive medication would have an impact on mortality akin to eliminating all deaths from medical errors or accidents.

They also speculate that "life expectancy would increase an additional 0.3 years (men) and 0.1 years (women) if therapy were extended to all with State I or Stage II hypertension not currently treated with medication."

Project FDA.
home   spotlight   commentary   research   events   news   about   contact   links   archives
Copyright Manhattan Institute for Policy Research
52 Vanderbilt Avenue
New York, NY 10017
(212) 599-7000